Literature DB >> 17920352

Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.

Sze Ting Lee1, Andrew M Scott.   

Abstract

The importance of hypoxia in disease pathogenesis and prognosis is gathering increasing clinical significance and having a greater impact on patient management and outcome. Previous efforts to evaluate hypoxia have included the invasive assessment of hypoxia with immunohistologic and histographic oxygen probes. The emergence of new radiotracers has allowed noninvasive assessment of hypoxia, with the most extensively investigated and validated positron emission tomography radiotracer of hypoxia to date being (18)F-fluoromisonodazole ((18)F-FMISO). This review discusses the relevance and biology of hypoxia in cells and organ systems, and reviews the laboratory and clinical applications of (18)F-FMISO in oncology and noncancer disease states.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17920352     DOI： 10.1053/j.semnuclmed.2007.07.001

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN： 0001-2998            Impact factor:   4.446


  91 in total

1.  ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.

Authors:  Kenji Hirata; Shunsuke Terasaka; Tohru Shiga; Naoya Hattori; Keiichi Magota; Hiroyuki Kobayashi; Shigeru Yamaguchi; Kiyohiro Houkin; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Authors:  Satish K Chitneni; Gerald T Bida; Mark W Dewhirst; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-06-22       Impact factor: 2.408

3.  Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.

Authors:  Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin
Journal:  NMR Biomed       Date:  2012-07-08       Impact factor: 4.044

Review 4.  Microfluidics for positron emission tomography probe development.

Authors:  Ming-Wei Wang; Wei-Yu Lin; Kan Liu; Michael Masterman-Smith; Clifton Kwang-Fu Shen
Journal:  Mol Imaging       Date:  2010-08       Impact factor: 4.488

Review 5.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 6.  Molecular imaging-its current role in cancer.

Authors:  S McDermott; A Kilcoyne
Journal:  QJM       Date:  2015-08-07

Review 7.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

8.  Tractable synthesis of multipurpose screening compounds with under-represented molecular features for an open access screening platform.

Authors:  Felix Wilde; Edgar Specker; Martin Neuenschwander; Marc Nazaré; Anja Bodtke; Andreas Link
Journal:  Mol Divers       Date:  2014-04-01       Impact factor: 2.943

Review 9.  The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.

Authors:  Renata Salgado Fernandes; Carolina de Aguiar Ferreira; Daniel Cristian Ferreira Soares; Anna Margherita Maffione; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2017-09-12       Impact factor: 6.529

Review 10.  The clinical utility of imaging methods used to measure hypoxia in cervical cancer.

Authors:  Joseph Waller; Benjamin Onderdonk; Ann Flood; Harold Swartz; Jaffer Shah; Asghar Shah; Bulent Aydogan; Howard Halpern; Yasmin Hasan
Journal:  Br J Radiol       Date:  2020-04-22       Impact factor: 3.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.